Index RUT P/E - EPS (ttm) -1.74 Insider Own 65.69% Shs Outstand 158.83M Perf Week -13.18%
Market Cap 2.23B Forward P/E - EPS next Y -1.56 Insider Trans -0.20% Shs Float 54.91M Perf Month 9.23%
Income -274.18M PEG - EPS next Q -0.39 Inst Own 27.62% Short Float 17.63% Perf Quarter 17.21%
Sales 0.00M P/S - EPS this Y 59.37% Inst Trans 18.05% Short Ratio 11.57 Perf Half Y 35.53%
Book/sh 2.38 P/B 5.86 EPS next Y -5.82% ROA -71.73% Short Interest 9.68M Perf Year 33.21%
Cash/sh 2.32 P/C 6.01 EPS next 5Y - ROE -77.08% 52W Range 8.33 - 21.00 Perf YTD -18.12%
Dividend Est. - P/FCF - EPS past 5Y - ROI -71.91% 52W High -33.52% Beta 3.88
Dividend TTM - Quick Ratio 17.22 Sales past 5Y 0.00% Gross Margin - 52W Low 67.59% ATR (14) 0.98
Dividend Ex-Date - Current Ratio 17.22 EPS Y/Y TTM -100.60% Oper. Margin 0.00% RSI (14) 47.85 Volatility 6.38% 7.10%
Employees 124 Debt/Eq 0.01 Sales Y/Y TTM - Profit Margin - Recom 1.00 Target Price 24.00
Option/Short Yes / Yes LT Debt/Eq 0.00 EPS Q/Q -45.53% Payout - Rel Volume 1.16 Prev Close 14.05
Sales Surprise - EPS Surprise 0.54% Sales Q/Q - Earnings Aug 06 BMO Avg Volume 836.82K Price 13.96
SMA20 -4.42% SMA50 8.76% SMA200 9.07% Trades
Volume 963,628 Change -0.64%
Date
Action
Analyst
Rating Change
Price Target Change
Oct-01-24 Initiated H.C. Wainwright
Buy
$30
Jul-22-24 Initiated Needham
Buy
$23
Jul-08-24 Initiated Mizuho
Outperform
$20
Dec-12-23 Initiated Deutsche Bank
Hold
$13
Oct-10-23 Initiated William Blair
Outperform
$26
Oct-10-23 Initiated Stifel
Buy
$26
Oct-10-23 Initiated RBC Capital Mkts
Outperform
$24
Oct-10-23 Initiated JP Morgan
Overweight
$21
Oct-10-23 Initiated Guggenheim
Buy
$22
Oct-10-23 Initiated BofA Securities
Buy
$18
Aug-14-24 07:00AM
Aug-06-24 01:54PM
07:00AM
Jul-01-24 01:00AM
Jun-20-24 07:00AM
08:52AM
Loading…
May-14-24 08:52AM
07:00AM
May-07-24 01:54PM
10:20AM
07:00AM
May-06-24 07:00AM
Apr-16-24 11:28AM
Apr-15-24 04:20PM
(Investor's Business Daily) -17.48%
12:17PM
08:45AM
07:47AM
Loading…
07:47AM
06:36AM
06:30AM
Mar-13-24 07:00AM
Mar-07-24 02:52PM
07:00AM
Jan-22-24 07:00AM
Jan-10-24 08:32AM
Jan-02-24 07:00AM
Dec-17-23 12:35PM
Dec-12-23 07:00AM
Nov-27-23 07:00AM
Nov-01-23 07:00AM
Oct-30-23 07:00AM
Oct-10-23 07:00AM
07:54PM
Loading…
Sep-28-23 07:54PM
(InvestorPlace) +11.84%
+6.73%
Sep-27-23 06:50PM
Sep-18-23 12:35PM
Sep-14-23 08:49PM
Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. It offers a precision medicine approach for brain diseases through the integration of data science and neuroscience. The firm focuses on advancing medicines for therapeutically relevant targets implicated in CNS diseases, targeting novel mechanisms of action with best-in-class pharmacology. The company was founded by Paul L. Berns, Carol Suh and Mike Poole in November 2019 and is headquartered in Watertown, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Fust Matthew K Director Oct 18 '24 Option Exercise 5.29 14,049 74,309 34,149 Oct 18 06:25 PM Fust Matthew K Director Oct 17 '24 Option Exercise 6.81 7,739 52,730 27,839 Oct 18 06:25 PM Fust Matthew K Director Oct 18 '24 Sale 17.03 14,049 239,319 20,100 Oct 18 06:25 PM Fust Matthew K Director Oct 17 '24 Sale 17.01 7,739 131,643 20,100 Oct 18 06:25 PM Fust Matthew K Director Oct 18 '24 Proposed Sale 17.03 14,049 239,319 Oct 18 04:01 PM Fust Matthew K Director Oct 17 '24 Proposed Sale 17.01 7,739 131,643 Oct 17 04:26 PM Lenz Robert A. Head of R&D Oct 10 '24 Sale 15.09 8,260 124,603 314,706 Oct 11 04:10 PM Lenz Robert A. Head of R&D Oct 09 '24 Sale 15.01 5,563 83,507 322,966 Oct 11 04:10 PM Lenz Robert A. Officer Oct 10 '24 Proposed Sale 15.09 8,260 124,603 Oct 10 04:30 PM Lenz Robert A. Officer Oct 09 '24 Proposed Sale 15.01 5,563 83,507 Oct 09 04:10 PM Lenz Robert A. Head of R&D Sep 17 '24 Sale 11.81 30,788 363,736 339,205 Sep 19 04:35 PM Lenz Robert A. Head of R&D Sep 18 '24 Sale 12.09 10,676 129,091 328,529 Sep 19 04:35 PM Lenz Robert A. Officer Sep 18 '24 Proposed Sale 12.09 10,676 129,091 Sep 18 04:27 PM Lenz Robert A. Officer Sep 17 '24 Proposed Sale 11.81 30,788 363,734 Sep 17 04:37 PM Lenz Robert A. Head of R&D Sep 12 '24 Sale 11.43 32,948 376,665 369,993 Sep 16 04:05 PM Lenz Robert A. Officer Sep 12 '24 Proposed Sale 11.43 32,948 376,665 Sep 12 05:18 PM Pinto Joshua Chief Financial Officer Aug 27 '24 Sale 11.39 15,693 178,806 138,965 Aug 27 05:58 PM Pinto Joshua Chief Financial Officer Aug 26 '24 Sale 11.78 31,642 372,588 154,658 Aug 26 06:17 PM Pinto Joshua Chief Financial Officer Aug 22 '24 Sale 11.63 28,496 331,468 210,469 Aug 26 06:17 PM Pinto Joshua Chief Financial Officer Aug 23 '24 Sale 11.59 24,169 280,005 186,300 Aug 26 06:17 PM Pinto Joshua Officer Aug 22 '24 Proposed Sale 11.90 100,000 1,190,000 Aug 22 09:48 AM Burow Kristina Director Nov 13 '23 Buy 11.75 31,653 371,923 4,127,850 Nov 15 06:55 PM Burow Kristina Director Nov 14 '23 Buy 11.98 3,357 40,217 4,131,207 Nov 15 06:55 PM ARCH Venture Partners XII, LLC 10% Owner Nov 13 '23 Buy 11.75 31,653 371,923 4,127,850 Nov 15 06:54 PM ARCH Venture Partners XII, LLC 10% Owner Nov 14 '23 Buy 11.98 3,357 40,217 4,131,207 Nov 15 06:54 PM Burow Kristina Director Nov 08 '23 Buy 11.03 92,251 1,017,821 4,047,843 Nov 13 07:01 PM Burow Kristina Director Nov 09 '23 Buy 10.53 31,079 327,262 4,078,922 Nov 13 07:01 PM Burow Kristina Director Nov 10 '23 Buy 11.49 17,275 198,481 4,096,197 Nov 13 07:01 PM ARCH Venture Partners XII, LLC 10% Owner Nov 08 '23 Buy 11.03 92,251 1,017,821 4,047,843 Nov 13 07:00 PM ARCH Venture Partners XII, LLC 10% Owner Nov 09 '23 Buy 10.53 31,079 327,262 4,078,922 Nov 13 07:00 PM ARCH Venture Partners XII, LLC 10% Owner Nov 10 '23 Buy 11.49 17,275 198,481 4,096,197 Nov 13 07:00 PM Burow Kristina Director Nov 06 '23 Buy 11.55 43,082 497,597 3,925,400 Nov 07 07:00 PM Burow Kristina Director Nov 07 '23 Buy 11.50 30,192 347,208 3,955,592 Nov 07 07:00 PM Burow Kristina Director Nov 03 '23 Buy 11.38 22,420 255,140 3,882,318 Nov 07 07:00 PM ARCH Venture Partners XII, LLC 10% Owner Nov 06 '23 Buy 11.55 43,082 497,597 3,925,400 Nov 07 06:59 PM ARCH Venture Partners XII, LLC 10% Owner Nov 07 '23 Buy 11.50 30,192 347,208 3,955,592 Nov 07 06:59 PM ARCH Venture Partners XII, LLC 10% Owner Nov 03 '23 Buy 11.38 22,420 255,140 3,882,318 Nov 07 06:59 PM
Index RUT P/E - EPS (ttm) -3.77 Insider Own 6.01% Shs Outstand 90.04M Perf Week 3.49%
Market Cap 5.37B Forward P/E - EPS next Y -3.86 Insider Trans -5.75% Shs Float 84.62M Perf Month 18.23%
Income -258.54M PEG - EPS next Q -0.91 Inst Own 89.39% Short Float 8.01% Perf Quarter 11.61%
Sales 0.00M P/S - EPS this Y -0.12% Inst Trans 2.39% Short Ratio 9.91 Perf Half Y 34.80%
Book/sh 10.47 P/B 5.69 EPS next Y -4.42% ROA -42.08% Short Interest 6.78M Perf Year 102.07%
Cash/sh 9.58 P/C 6.22 EPS next 5Y - ROE -47.66% 52W Range 25.75 - 59.80 Perf YTD 67.54%
Dividend Est. - P/FCF - EPS past 5Y -10.59% ROI -29.49% 52W High -0.32% Beta 0.63
Dividend TTM - Quick Ratio 16.09 Sales past 5Y 64.83% Gross Margin -105.50% 52W Low 131.50% ATR (14) 2.09
Dividend Ex-Date - Current Ratio 16.09 EPS Y/Y TTM -10.61% Oper. Margin 0.00% RSI (14) 70.43 Volatility 2.97% 3.96%
Employees 290 Debt/Eq 0.06 Sales Y/Y TTM -100.00% Profit Margin - Recom 1.21 Target Price 69.21
Option/Short Yes / Yes LT Debt/Eq 0.06 EPS Q/Q 0.21% Payout - Rel Volume 1.62 Prev Close 58.70
Sales Surprise -14.62% EPS Surprise -9.44% Sales Q/Q - Earnings Nov 12 AMC Avg Volume 683.76K Price 59.61
SMA20 10.42% SMA50 12.39% SMA200 27.73% Trades
Volume 1,101,359 Change 1.55%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-06-24 Initiated Citigroup
Buy
$68
Jan-16-24 Initiated Morgan Stanley
Overweight
$50
Dec-21-23 Initiated Jefferies
Hold
$35
Nov-20-23 Resumed JP Morgan
Overweight
$35
Oct-24-23 Resumed Cantor Fitzgerald
Overweight
$52 → $50
Aug-31-23 Initiated Oppenheimer
Outperform
$40
Apr-24-23 Initiated Piper Sandler
Overweight
$56
Mar-30-23 Initiated Robert W. Baird
Outperform
$48
Nov-30-21 Initiated JMP Securities
Mkt Outperform
$43
Nov-23-21 Initiated Evercore ISI
Outperform
$68
Jun-18-21 Upgrade JP Morgan
Neutral → Overweight
$28
Dec-23-19 Initiated ROTH Capital
Buy
$37
Feb-14-19 Initiated H.C. Wainwright
Buy
$35
Aug-13-18 Initiated Piper Jaffray
Overweight
$40
Aug-13-18 Initiated Leerink Partners
Outperform
$43
Aug-13-18 Initiated JP Morgan
Neutral
$29
Show Previous Ratings
Oct-17-24 03:09PM
Oct-16-24 08:00AM
Oct-10-24 04:40PM
08:57AM
Oct-09-24 05:56PM
11:55PM
Loading…
Oct-08-24 11:55PM
04:01PM
Sep-26-24 04:05PM
Sep-12-24 07:00PM
Sep-10-24 04:40PM
Sep-05-24 01:07AM
Sep-02-24 06:05PM
Aug-29-24 04:05PM
Aug-28-24 07:01PM
Aug-14-24 07:02PM
04:05PM
Loading…
Aug-12-24 04:05PM
Aug-08-24 09:57PM
(InvestorPlace) +5.05%
-6.11%
06:00PM
04:05PM
08:30AM
Aug-01-24 10:01AM
Jul-26-24 07:00PM
Jul-18-24 04:05PM
Jul-12-24 07:01PM
Jul-10-24 07:29PM
Jun-26-24 07:00PM
02:11PM
Jun-18-24 04:30PM
Jun-12-24 02:38AM
Jun-10-24 06:35PM
12:16PM
Loading…
Jun-03-24 12:16PM
(Investor's Business Daily)
12:00PM
12:00PM
May-31-24 02:46AM
May-30-24 04:05PM
May-22-24 08:00AM
May-16-24 05:23PM
May-13-24 10:53AM
May-10-24 05:38PM
05:03PM
12:47PM
May-09-24 08:55PM
05:35PM
05:03PM
04:05PM
May-08-24 04:05PM
May-07-24 08:55AM
May-02-24 04:05PM
Apr-11-24 04:05PM
Mar-28-24 08:10AM
Mar-26-24 07:01PM
Mar-22-24 07:02PM
07:02PM
Mar-21-24 02:32AM
Mar-20-24 11:46AM
05:14AM
Mar-19-24 04:48PM
04:03PM
(Investor's Business Daily)
08:08AM
(Investor's Business Daily)
06:16AM
06:08AM
06:00AM
Mar-12-24 04:05PM
Mar-11-24 04:05PM
Mar-01-24 08:57AM
Feb-28-24 04:36PM
04:05PM
08:00AM
Feb-15-24 03:14AM
Feb-14-24 04:05PM
Feb-12-24 04:05PM
Jan-26-24 11:01PM
Jan-13-24 05:03AM
Jan-10-24 04:33PM
Jan-05-24 03:03AM
Jan-03-24 08:00AM
Dec-29-23 07:02AM
Dec-23-23 05:01AM
Dec-18-23 04:05PM
Dec-11-23 04:05PM
Dec-03-23 05:25AM
Nov-20-23 04:05PM
Nov-17-23 08:39AM
Nov-10-23 05:00PM
Nov-09-23 05:45AM
Nov-08-23 09:55AM
08:50AM
Nov-07-23 04:05PM
Nov-04-23 05:03AM
Oct-23-23 09:55AM
08:50AM
Oct-20-23 01:02AM
Oct-11-23 09:00AM
Oct-10-23 05:00PM
Oct-03-23 07:00AM
Sep-28-23 11:18AM
Sep-20-23 08:00AM
Sep-15-23 08:37AM
Sep-12-23 10:26PM
(GlobeNewswire) +17.29%
-6.70%
Sep-11-23 04:04PM
(Investor's Business Daily) +63.31%
Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Pizzuti Dana Chief Med and Dev Officer Oct 03 '24 Option Exercise 16.89 14,375 242,794 42,882 Oct 07 07:55 AM Pizzuti Dana Chief Med and Dev Officer Oct 03 '24 Sale 54.63 14,375 785,306 28,507 Oct 07 07:55 AM DANA J PIZZUTI Officer Oct 03 '24 Proposed Sale 54.63 14,375 785,322 Oct 03 04:08 PM Wilson Marc CFO Sep 26 '24 Option Exercise 15.29 25,000 382,250 136,092 Sep 30 05:01 PM Wilson Marc CFO Sep 26 '24 Sale 51.11 25,000 1,277,750 111,092 Sep 30 05:01 PM MARC WILSON Officer Sep 26 '24 Proposed Sale 51.10 25,000 1,277,625 Sep 26 04:06 PM Betz Stephen F. Chief Scientific Officer Sep 10 '24 Sale 51.50 1,035 53,302 68,576 Sep 12 04:30 PM Betz Stephen F. Officer Sep 10 '24 Proposed Sale 51.50 1,035 53,301 Sep 10 12:11 PM Betz Stephen F. Chief Scientific Officer Aug 26 '24 Sale 53.19 3,000 159,570 69,611 Aug 28 04:31 PM Betz Stephen F. Officer Aug 26 '24 Proposed Sale 53.19 3,000 159,570 Aug 26 01:16 PM Betz Stephen F. Chief Scientific Officer Aug 12 '24 Sale 47.68 3,000 143,040 72,611 Aug 14 04:30 PM Betz Stephen F. Officer Aug 12 '24 Proposed Sale 47.68 3,000 143,050 Aug 12 11:35 AM Betz Stephen F. Chief Scientific Officer Jul 25 '24 Sale 53.43 3,000 160,290 75,611 Jul 26 04:38 PM Wilson Marc CFO Jul 25 '24 Option Exercise 9.28 19,056 176,840 130,148 Jul 26 04:24 PM Wilson Marc CFO Jul 25 '24 Sale 53.88 19,056 1,026,737 111,092 Jul 26 04:24 PM Knight Jeff E. Chief Operating Officer Jul 15 '24 Option Exercise 22.59 26,073 589,116 78,653 Jul 17 05:35 PM Knight Jeff E. Chief Operating Officer Jul 15 '24 Sale 55.00 27,000 1,485,000 51,653 Jul 17 05:35 PM Wilson Marc CFO Jul 15 '24 Option Exercise 20.02 25,000 500,500 136,092 Jul 17 05:14 PM Wilson Marc CFO Jul 15 '24 Sale 55.00 25,000 1,375,000 111,092 Jul 17 05:14 PM Betz Stephen F. Chief Scientific Officer Jul 10 '24 Sale 48.55 3,000 145,650 78,611 Jul 12 04:30 PM Hassard James Chief Commercial Officer Jul 05 '24 Option Exercise 19.73 15,000 295,950 44,259 Jul 09 06:04 PM Hassard James Chief Commercial Officer Jul 05 '24 Sale 44.08 15,000 661,200 29,259 Jul 09 06:04 PM Pizzuti Dana Chief Med and Dev Officer Jul 03 '24 Option Exercise 16.89 14,375 242,794 42,882 Jul 05 04:30 PM Pizzuti Dana Chief Med and Dev Officer Jul 03 '24 Sale 44.87 14,375 645,006 28,507 Jul 05 04:30 PM Wilson Marc CFO Jun 28 '24 Option Exercise 9.28 32,129 298,157 143,221 Jul 02 04:32 PM Wilson Marc CFO Jun 28 '24 Sale 43.61 32,129 1,401,146 111,092 Jul 02 04:32 PM Knight Jeff E. Chief Operating Officer Jun 26 '24 Sale 44.38 956 42,427 52,580 Jun 28 05:31 PM Betz Stephen F. Chief Scientific Officer Jun 25 '24 Sale 45.37 3,000 136,110 80,643 Jun 26 04:32 PM Pizzuti Dana Chief Med and Dev Officer Jun 24 '24 Option Exercise 16.89 9,500 160,455 37,286 Jun 25 05:03 PM Pizzuti Dana Chief Med and Dev Officer Jun 24 '24 Sale 45.73 9,500 434,435 27,786 Jun 25 05:03 PM Hassard James Chief Commercial Officer Jun 21 '24 Option Exercise 19.73 15,000 295,950 44,259 Jun 24 05:08 PM Hassard James Chief Commercial Officer Jun 21 '24 Sale 44.66 15,000 669,900 29,259 Jun 24 05:08 PM Betz Stephen F. Chief Scientific Officer Jun 10 '24 Sale 43.86 3,000 131,580 83,643 Jun 11 04:35 PM Betz Stephen F. Chief Scientific Officer May 28 '24 Sale 47.49 3,000 142,470 86,643 May 30 04:28 PM Betz Stephen F. Chief Scientific Officer May 10 '24 Sale 49.43 3,000 148,290 89,643 May 14 06:29 PM Struthers Richard Scott President & CEO May 08 '24 Option Exercise 9.28 107,448 997,117 364,933 May 10 04:57 PM Struthers Richard Scott President & CEO May 08 '24 Sale 49.40 107,448 5,307,931 257,485 May 10 04:57 PM Pizzuti Dana Chief Med and Dev Officer Apr 15 '24 Option Exercise 16.89 14,375 242,794 42,161 Apr 17 04:36 PM Pizzuti Dana Chief Med and Dev Officer Apr 15 '24 Sale 44.47 14,375 639,256 27,786 Apr 17 04:36 PM Struthers Richard Scott President & CEO Apr 15 '24 Option Exercise 1.91 20,000 38,200 257,835 Apr 17 04:30 PM Struthers Richard Scott President & CEO Apr 04 '24 Option Exercise 9.28 40,951 380,025 278,786 Apr 08 05:09 PM Struthers Richard Scott President & CEO Apr 04 '24 Sale 49.17 40,951 2,013,561 237,835 Apr 08 05:09 PM Okey Stephanie Director Mar 28 '24 Option Exercise 18.29 17,500 320,075 23,500 Apr 02 04:35 PM Okey Stephanie Director Mar 28 '24 Sale 46.38 17,500 811,650 6,000 Apr 02 04:35 PM Knight Jeff E. Chief Operating Officer Mar 22 '24 Option Exercise 23.98 30,000 719,400 84,939 Mar 26 04:30 PM Knight Jeff E. Chief Operating Officer Mar 22 '24 Sale 44.31 32,359 1,433,675 52,580 Mar 26 04:30 PM Pizzuti Dana Chief Med and Dev Officer Mar 20 '24 Option Exercise 16.89 14,375 242,794 38,500 Mar 22 04:52 PM Pizzuti Dana Chief Med and Dev Officer Mar 20 '24 Sale 44.06 15,089 664,763 27,786 Mar 22 04:52 PM Fust Matthew K Director Mar 20 '24 Option Exercise 20.92 60,000 1,254,975 36,036 Mar 22 04:31 PM Fust Matthew K Director Mar 20 '24 Sale 44.14 60,000 2,648,150 18,536 Mar 22 04:31 PM Wilson Marc CFO Mar 19 '24 Sale 42.91 6,942 297,881 110,630 Mar 20 06:32 PM Betz Stephen F. Chief Scientific Officer Jan 25 '24 Sale 37.26 3,000 111,780 73,298 Jan 26 05:50 PM Betz Stephen F. Chief Scientific Officer Jan 10 '24 Sale 37.65 3,000 112,950 76,298 Jan 12 04:12 PM Pizzuti Dana Chief Med and Dev Officer Jan 03 '24 Option Exercise 16.89 14,375 242,794 20,286 Jan 04 04:45 PM Pizzuti Dana Chief Med and Dev Officer Jan 03 '24 Sale 35.00 14,375 503,125 5,911 Jan 04 04:45 PM Wilson Marc CFO Jan 02 '24 Option Exercise 9.28 10,000 92,800 106,055 Jan 04 04:43 PM Wilson Marc CFO Jan 02 '24 Sale 35.47 10,000 354,700 96,055 Jan 04 04:43 PM Betz Stephen F. Chief Scientific Officer Dec 26 '23 Sale 35.89 3,000 107,670 79,298 Dec 27 05:20 PM Pizzuti Dana Chief Med and Dev Officer Dec 21 '23 Option Exercise 16.89 9,583 161,857 15,494 Dec 22 06:45 PM Pizzuti Dana Chief Med and Dev Officer Dec 21 '23 Sale 34.57 9,583 331,284 5,911 Dec 22 06:45 PM Betz Stephen F. Chief Scientific Officer Dec 11 '23 Sale 32.87 3,000 98,610 82,298 Dec 13 04:44 PM Betz Stephen F. Chief Scientific Officer Nov 27 '23 Sale 31.84 3,000 95,520 85,298 Nov 29 04:31 PM Struthers Richard Scott President & CEO Nov 09 '23 Option Exercise 1.91 50,000 95,500 185,522 Nov 13 04:33 PM Struthers Richard Scott President & CEO Nov 03 '23 Option Exercise 9.28 199,082 1,847,481 334,604 Nov 06 06:02 PM Struthers Richard Scott President & CEO Nov 02 '23 Option Exercise 9.28 918 8,519 136,440 Nov 06 06:02 PM Struthers Richard Scott President & CEO Nov 03 '23 Sale 30.56 199,082 6,083,946 135,522 Nov 06 06:02 PM Struthers Richard Scott President & CEO Nov 02 '23 Sale 29.95 918 27,494 135,522 Nov 06 06:02 PM Wilson Marc CFO Nov 01 '23 Option Exercise 9.28 10,000 92,800 105,601 Nov 03 07:38 PM Wilson Marc CFO Nov 01 '23 Sale 28.75 10,000 287,500 95,601 Nov 03 07:38 PM
Index - P/E - EPS (ttm) -7.29 Insider Own 6.46% Shs Outstand 92.17M Perf Week -4.08%
Market Cap 5.05B Forward P/E - EPS next Y -5.28 Insider Trans -1.00% Shs Float 86.21M Perf Month -4.81%
Income -585.12M PEG - EPS next Q -1.48 Inst Own 96.70% Short Float 3.35% Perf Quarter 21.46%
Sales 481.30M P/S 10.49 EPS this Y 22.42% Inst Trans 10.70% Short Ratio 4.26 Perf Half Y 21.46%
Book/sh 4.70 P/B 11.67 EPS next Y 17.55% ROA -39.94% Short Interest 2.89M Perf Year 65.43%
Cash/sh 8.35 P/C 6.56 EPS next 5Y 37.90% ROE -208.43% 52W Range 31.52 - 60.37 Perf YTD 14.58%
Dividend Est. - P/FCF - EPS past 5Y -15.75% ROI -45.00% 52W High -9.24% Beta 0.57
Dividend TTM - Quick Ratio 3.39 Sales past 5Y 63.06% Gross Margin 83.47% 52W Low 73.83% ATR (14) 1.68
Dividend Ex-Date - Current Ratio 3.54 EPS Y/Y TTM 28.85% Oper. Margin -114.03% RSI (14) 47.17 Volatility 2.71% 3.05%
Employees 1276 Debt/Eq 2.14 Sales Y/Y TTM 19.47% Profit Margin -121.57% Recom 1.20 Target Price 92.10
Option/Short Yes / Yes LT Debt/Eq 2.01 EPS Q/Q 32.57% Payout - Rel Volume 0.51 Prev Close 54.46
Sales Surprise 19.34% EPS Surprise 8.47% Sales Q/Q 35.75% Earnings Aug 01 AMC Avg Volume 677.50K Price 54.79
SMA20 -0.64% SMA50 -1.82% SMA200 15.13% Trades
Volume 374,760 Change 0.61%
Date
Action
Analyst
Rating Change
Price Target Change
Jun-06-24 Upgrade Goldman
Neutral → Buy
$56 → $67
Apr-22-24 Initiated RBC Capital Mkts
Outperform
$77
Dec-08-23 Initiated Wells Fargo
Overweight
$72
Jun-14-23 Resumed Credit Suisse
Outperform
$96
Jun-06-23 Upgrade Evercore ISI
In-line → Outperform
$60 → $80
Apr-26-23 Initiated Cantor Fitzgerald
Overweight
$114
Jan-18-23 Resumed Canaccord Genuity
Buy
$90
Dec-30-22 Resumed H.C. Wainwright
Buy
$82
Nov-03-22 Upgrade Robert W. Baird
Neutral → Outperform
$50
Oct-13-22 Upgrade Guggenheim
Neutral → Buy
$50
Aug-01-22 Downgrade Evercore ISI
Outperform → In-line
$95 → $60
Mar-16-22 Upgrade Credit Suisse
Neutral → Outperform
$99 → $105
Feb-11-22 Upgrade JP Morgan
Neutral → Overweight
$132
Sep-30-21 Initiated H.C. Wainwright
Buy
$106
Aug-19-21 Initiated UBS
Sell
$73
Jul-15-21 Initiated Guggenheim
Neutral
Jun-29-21 Upgrade BofA Securities
Neutral → Buy
$162
Jun-04-21 Resumed Robert W. Baird
Neutral
$109
May-06-21 Upgrade Evercore ISI
In-line → Outperform
$144
May-06-21 Upgrade Citigroup
Neutral → Buy
$160 → $151
Show Previous Ratings
Oct-18-24 04:30PM
Oct-07-24 08:00AM
Oct-03-24 04:30PM
Sep-26-24 08:00AM
Sep-18-24 05:00PM
01:07AM
Loading…
Sep-05-24 01:07AM
Sep-02-24 06:05PM
Aug-29-24 04:30PM
Aug-21-24 04:30PM
Aug-06-24 10:45AM
Aug-02-24 08:15AM
07:44AM
Aug-01-24 04:17PM
(Associated Press Finance)
04:05PM
Jul-25-24 04:05PM
08:00AM
Loading…
Jul-24-24 08:00AM
Jul-22-24 04:27PM
(Investor's Business Daily)
Jul-19-24 04:05PM
Jul-18-24 09:03AM
Jul-17-24 04:05PM
Jun-20-24 04:30PM
Jun-17-24 03:27PM
Jun-13-24 08:49PM
10:15AM
05:12AM
03:14AM
Jun-12-24 04:05PM
04:00PM
10:46AM
07:45AM
05:47PM
Loading…
Jun-11-24 05:47PM
Jun-04-24 04:05PM
May-31-24 10:36AM
May-30-24 04:00PM
May-22-24 02:27PM
May-17-24 04:30PM
May-07-24 04:30PM
May-04-24 10:24AM
May-03-24 03:01PM
12:22PM
May-02-24 08:58PM
08:00PM
05:49PM
05:10PM
04:08PM
(Associated Press Finance)
04:00PM
Apr-30-24 04:00PM
08:00AM
Apr-25-24 04:30PM
Apr-19-24 04:30PM
Apr-16-24 11:33AM
Apr-15-24 07:30AM
07:00AM
Apr-12-24 04:22PM
08:00AM
Mar-22-24 04:00PM
Mar-20-24 08:11AM
Mar-12-24 05:00PM
Mar-11-24 03:00PM
Mar-08-24 09:38AM
Feb-27-24 04:30PM
Feb-23-24 04:05PM
Feb-16-24 10:43AM
10:35AM
(Thomson Reuters StreetEvents)
07:53AM
Feb-15-24 04:15PM
(Associated Press Finance)
04:01PM
Feb-13-24 01:36PM
Feb-08-24 04:00PM
Feb-06-24 08:00AM
Feb-05-24 04:05PM
Jan-25-24 04:05PM
Jan-19-24 04:00PM
Jan-18-24 02:41PM
(Investor's Business Daily)
Jan-09-24 06:20PM
Jan-08-24 12:18PM
07:00AM
Jan-07-24 11:00AM
Jan-04-24 08:12AM
08:00AM
Jan-03-24 08:00AM
Jan-02-24 04:05PM
Dec-27-23 06:41PM
Dec-21-23 05:21PM
(The Wall Street Journal)
04:30PM
Dec-18-23 09:29AM
08:00AM
Dec-15-23 10:18AM
Nov-20-23 04:30PM
Nov-17-23 04:30PM
Nov-07-23 05:00PM
Nov-04-23 01:12PM
12:16PM
Nov-03-23 11:43AM
Nov-02-23 06:26PM
04:36PM
(Associated Press Finance)
04:05PM
Oct-26-23 04:05PM
Oct-25-23 06:17AM
Oct-23-23 04:01PM
Ultragenyx Pharmaceutical, Inc. engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010, and is headquartered in Novato, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Horn Howard Chief Financial Officer Oct 10 '24 Sale 52.76 7,465 393,853 92,301 Oct 11 04:48 PM KAKKIS EMIL D President & CEO Sep 03 '24 Sale 55.85 20,000 1,117,000 2,223,985 Sep 05 11:53 AM Huizenga Theodore Alan SVP, Chief Accounting Officer Sep 03 '24 Sale 56.19 91 5,113 41,551 Sep 05 11:50 AM KAKKIS EMIL D Officer Sep 03 '24 Proposed Sale 55.85 20,000 1,117,096 Sep 03 04:40 PM KAKKIS EMIL D President & CEO Aug 06 '24 Sale 50.17 20,000 1,003,400 2,243,985 Aug 07 02:48 PM KAKKIS EMIL D Officer Aug 06 '24 Proposed Sale 50.17 20,000 1,003,418 Aug 06 04:28 PM Sanders Corazon (Corsee) D. Director Jul 02 '24 Sale 40.98 584 23,932 12,009 Jul 03 02:07 PM Parschauer Karah Herdman EVP and Chief Legal Officer Jun 12 '24 Sale 45.00 9,806 441,270 57,981 Jun 12 07:47 PM Sanders Corazon (Corsee) D. Director Jun 10 '24 Sale 41.10 1,737 71,391 7,248 Jun 10 07:58 PM Crombez Eric EVP and Chief Medical Officer May 02 '24 Sale 43.66 354 15,456 48,431 May 03 03:23 PM Crombez Eric EVP and Chief Medical Officer Apr 18 '24 Sale 44.10 142 6,262 48,785 Apr 19 04:35 PM Kassberg Thomas Richard CBO & EVP Mar 11 '24 Sale 49.93 11,509 574,644 252,823 Mar 12 01:41 PM Fust Matthew K Director Mar 07 '24 Sale 50.88 12,195 620,443 14,860 Mar 11 12:54 PM Parschauer Karah Herdman EVP and Chief Legal Officer Mar 01 '24 Sale 53.76 3,756 201,923 67,340 Mar 05 08:22 PM Kassberg Thomas Richard CBO & EVP Mar 01 '24 Sale 53.76 1,011 54,351 264,332 Mar 05 08:19 PM Pinion John Richard See Remarks Mar 01 '24 Sale 53.76 4,173 224,340 89,268 Mar 05 08:15 PM Huizenga Theodore Alan SVP, Chief Accounting Officer Mar 01 '24 Sale 53.76 341 18,332 41,380 Mar 05 08:13 PM Crombez Eric EVP and Chief Medical Officer Mar 01 '24 Sale 53.76 1,238 66,555 48,927 Mar 05 08:10 PM Harris Erik EVP & Chief Commercial Officer Mar 01 '24 Sale 53.76 4,768 256,328 67,163 Mar 05 08:08 PM KAKKIS EMIL D President & CEO Feb 07 '24 Sale 45.00 30,000 1,350,000 539,770 Feb 08 03:49 PM KAKKIS EMIL D President & CEO Dec 29 '23 Sale 47.87 30,000 1,436,100 569,770 Jan 02 04:07 PM Huizenga Theodore Alan SVP, Chief Accounting Officer Jan 02 '24 Option Exercise 21.00 3,000 63,000 27,892 Jan 02 04:06 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
